SA JOURNAL OF DIABETES & VASCULAR DISEASE
EDITORIAL
VOLUME 7 NUMBER 2 • JUNE 2010
53
based therapies for the treatment of type 2 diabetes: evaluation of the risks and
benefits.
Diabetes Care
2010;
33
: 428–433.
Nauck M. GLP-1 and GLP-1-based therapies: Addressing beta-cell dysfunction in
4.
type 2 diabetes.
S Afr J Diabetes Vasc Dis
2009;
6
: 100–106.
Peters A. Incretin-based therapies: review of current clinical trial data.
5.
Am J Med
2010;
123
: S28–S37.
Nauck MA, Heimeaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeld W. Preserved
6.
incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic
human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus.
J
Clin Invest
1993;
91
: 301–307.
Mafong DD, Henry RR. The role of incretins in cardiovascular control.
7.
Curr
Hypertens Rep
2009;
11
: 18–22.
Mudaliar, S, Henry RR. Effects of incretin hormones on
8.
β
-cell mass and function,
body weight, and hepatic and myocardial function.
Am J Med
2010;
123
: S19–
S27.
Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with
9.
glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Curr Diabetes Rev
2009;
5
: 266–275.
Faradji RN, Froud T, Messinger S, Monroy K, Pileggi A, Mineo D,
10.
et al
. Long-term
metabolic and hormonal effects of exenatide on islet transplant recipients with
allograft dysfunction.
Cell Transplant
2009;
18
: 1247–1259.
Hoffmann T, Glund K, McIntosh CHS, Pederson RA, Hanefeld M, Rosenkranz B,
11.
Demuth H-U. DPPIV-inhibition as treatment of type II diabetes. In: Mizutani S,
et
al
. (eds)
Cell-surface Aminopeptidases: Basic and Clinical Aspects
. Amsterdam:
Elsevier Health Sciences, 2001; 381–387.
European Medicines Agency. European Public Assessment Report (Byetta,
12.
exenatide):
PI-en.pdf, accessed 30 April 2010.
DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell
13.
L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and
glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-
over study.
Curr Med Res Opin
2008;
24
: 2943–2952.
Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based
14.
therapy: therapeutic potential, patient selection and clinical use.
Eur J Int Med
2009;
20
: S329–S339.
Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor
15.
agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Eur J
Endocrinol
2009;
160
: 909–917.
Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM,
16.
et al
. One-
year treatment with exenatide improves beta-cell function, compared with insulin
glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled
trial.
Diabetes Care
2009;
32
: 762–768.
Koch CA, Uwaifo GI. Are gastrointestinal symptoms related to diabetes mellitus
17.
and glycaemic control?
Eur J Gastroenterol Hepatol
2008;
20
: 822–825.
Comments: Exenatide and rare adverse events.
18.
N Eng J Med
2008;
358
:1969–
1972.
Dore DD, Seenger JD, Arnold Chan K. Use of a claims-based active drug
19.
surveillance system to assess the risk of acute pancreatitis with exenatide or
sitagliptin compared to metformin or glyburide.
Curr Med Res Opin
2009;
25
:
1019–1027.
Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: What you do not
20.
know can hurt you.
Diabetes Care
2010;
33
: 453–455.
FDA MedWatch. Byetta – Renal failure.
/
21.
SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm,
accessed 30 April 2010.
Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal
22.
failure.
Diabetes Care
2009;
32
: e22–e23.
Linnebjerg, H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect
23.
of renal impairment on the pharmacokinetics of exenatide.
Br J Clin Pharmacol
2007;
64
: 317–327.
Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK. The effect of exenatide
24.
re-exposure on safety and efficacy.
Peptides
2009;
30
: 1771–1774.
Misurski D, Lage MJ, Fabunmi R, Boye KS. A comparison of costs among patients
25.
with type 2 diabetes mellitus who initiated therapy with exenatide or insulin
glargine.
Appl Hlth Econ Hlth Policy
2009;
7
: 245–254.
Lage MJ, Fabunmi R, Boye KS, Misurski DA. Comparison of costs among patients
26.
with type 2 diabetes treated with exenatide or sitagliptin therapy.
Adv Ther
2009;
26
: 217–229.
Woehl A, Evans M, Tetlow AP, McEwan P. Evaluation of the cost effectiveness of
27.
exenatide versus insulin glargine in patients with sub-optimally controlled type 2
diabetes in the United Kingdom.
Cardiovasc Diabetol
2008;
7
: 24.
Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ. Estimating
28.
the long-term cost effectiveness of exenatide in the United States: An adjunctive
treatment for type 2 diabetes mellitus.
Value Hlth
2008;
11
: 22–33.
Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment
29.
of type 2 diabetes mellitus, 1994-2007.
Arch Intern Med
2008;
168
: 2088–
2094.
Rosenstock J, Fonseca V. Missing the point: Substituting exenatide for
30.
nonoptimized insulin.
Diabetes Care
2007;
30
: 2972–2973.
Adler AI, Shaw EJ, Stokes T, Ruiz F. Newer agents for blood glucose control in
31.
type 2 diabetes: Summary of NICE guidance.
Br Med J
2009;
338
: 1328–1329.
Idria I. National Institute of Clinical Excellence provides an update on the clinical
32.
management of patients with type 2 diabetes.
Diabetes Obes Metab
2008;
10
:
605–606.
